Cite
Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies.
MLA
Orbach, Daniel, et al. “Spotlight on the Treatment of Infantile Fibrosarcoma in the Era of Neurotrophic Tropomyosin Receptor Kinase Inhibitors: International Consensus and Remaining Controversies.” European Journal of Cancer, vol. 137, Sept. 2020, pp. 183–92. EBSCOhost, https://doi.org/10.1016/j.ejca.2020.06.028.
APA
Orbach, D., Sparber-Sauer, M., Laetsch, T. W., Minard-Colin, V., Bielack, S. S., Casanova, M., Corradini, N., Koscielniak, E., Scheer, M., Hettmer, S., Bisogno, G., Hawkins, D. S., & Ferrari, A. (2020). Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies. European Journal of Cancer, 137, 183–192. https://doi.org/10.1016/j.ejca.2020.06.028
Chicago
Orbach, Daniel, Monika Sparber-Sauer, Theodore W. Laetsch, Veronique Minard-Colin, Stefan S. Bielack, Michela Casanova, Nadege Corradini, et al. 2020. “Spotlight on the Treatment of Infantile Fibrosarcoma in the Era of Neurotrophic Tropomyosin Receptor Kinase Inhibitors: International Consensus and Remaining Controversies.” European Journal of Cancer 137 (September): 183–92. doi:10.1016/j.ejca.2020.06.028.